PRAX · NASDAQ · STOCK
Praxis Precision Medicines (PRAX) Stock Analysis
$259.95
52W $50.56 – $392.70
52/100
$7.24B
-20.1
2.81
Is PRAX Bullish or Bearish?
Mixed.
Innellis AI committee rates Praxis Precision Medicines, Inc. (PRAX) Watch with a composite score of 52/100
, based on 5 analysts with 60% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +7.67 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -12.33 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
Bear Case
- Price-to-book of 8.4x prices in significant intangible value — Value
- ROE of only -43.0% -- cheap may mean cheap for a reason — Value
- RSI at 21 is in oversold territory (could mean either capitulation or a bounce setup) — Technical
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 23.3% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
52/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 84%
of 192 Healthcare peers
Value Analyst
neutral
43
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− Price-to-book of 8.4x prices in significant intangible value
Technical Analyst
bearish
38
/ 100 · High confidence
Price action is deteriorating -- trend and/or momentum are working against this name
− RSI at 21 is in oversold territory (could mean either capitulation or a bounce setup)
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 23.3% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 52.3 to 52.3.
- New bearish signals: 2 appeared.
- Bearish pressure eased: 2 signal(s) disappeared.
Analyst-level changes:
- Risk Analyst: +1 bearish signal(s).
- Technical Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
21.3
Oversold
MACD Histogram
-1.371
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Support
$239.87
Resistance
$352.78
Bollinger %B
0.05
Inside Bands
Price vs Moving Averages
EMA 9
$277.48
Below
EMA 21
$293.61
Below
EMA 50
$312.22
Below
EMA 200
$290.68
Below
Fundamental Analysis
Valuation
45
Growth
61
Profitability
0
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-20.1×
P/B Ratio
5.64×
PEG Ratio
3.57
Dividend Yield
0.00%
52W High
$392.70
52W Low
$50.56
Quality & Growth
ROE
-3453.5%
ROA
-3233.4%
Gross Margin
0.0%
Operating Margin
0.0%
Revenue Growth YoY
—
Debt / Equity
0.00
AI Fundamental Assessment
P/E ratio of -20.1 (inexpensive relative to a 15-40x range); Price-to-book of 5.6x; PEG ratio of 3.6 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -34.5%; Return on assets of -32.3%; Net margin of 0.0%; Gross margin of 0.0%; Current ratio of 15.73 (healthy short-term liquidity); Debt-to-equity of 0.00; Free cash flow per share is negative (-10.50); Most recent quarter beat estimates by 23.1%; 2 consecutive earnings beats; EPS growth roughly steady (+8.6% -> +10.3% QoQ); Analyst estimates falling over recent quarters
Get the Full PRAX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →